Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Completed · Phase 1 · Has a placebo group

Conditions studied: Glaucoma, Open-Angle, Ocular Hypertension

In brief

This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.

Key facts

Study ID

NCT01215786

Run by

Allergan

People needed

50

Starts

2010-10-01

Expected to finish

2010-12-01

Last updated by the study team

2015-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or primary open-angle glaucoma in each eye
• Requires IOP-lowering therapy in both eyes
• Visual acuity score of 20/100 or better in each eye

You may not qualify if…

• Experienced significant weight change (over 10 pounds) within 60 days
• History of alcohol or drug addiction
• History of migraines or frequent headaches
• Anticipated wearing of contact lenses during the study
• Required chronic use of ocular medications during study
• Eye surgery within 6 months
• Use of systemic beta blockers (eg, atenolol, propranolol) within 2 months
• Use of oral, intramuscular, intravenous corticosteroids within 21 days
• Use of ophthalmic corticosteroids within 2 months

Where it is running

• Study site — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.